SB 207 establishes the Oklahoma Rare Disease Advisory Council within the State Department of Health to address the needs of Oklahomans living with rare diseases (defined as conditions affecting fewer than 200,000 people nationally). The Council, composed of 13 diverse members including patients, caregivers, healthcare providers, researchers, and industry representatives, will conduct public hearings, develop policy recommendations, and create emergency care protocols to improve access to specialists, diagnostics, and equitable treatment. The bill also modifies Oklahoma’s newborn screening program to require an educational initiative for treatable genetic disorders, aiming to prevent intellectual disabilities and reduce infant mortality through early intervention. This legislation directly affects rare disease patients, their families, healthcare providers, and state agencies responsible for public health programs in Oklahoma.
HB 2645 creates a tax credit for qualifying doctors practicing medicine in rural Oklahoma, directly affecting licensed physicians who meet specific residency and education criteria. The credit, capped at $20,000 per year per doctor, applies to taxable income from medical practice in designated rural areas (population under 25,000 and at least 25 miles from larger cities). The bill includes an annual $1 million total credit limit, with adjustments to prevent exceeding this cap. The bill was pocket-vetoed by the governor on June 15, 2025, and never became law.
HB 2788 transfers specific funds back into Oklahoma's Statewide Recovery Fund from several existing programs. It moves $1.56 million from domestic violence services, $162,668 from food assistance programs, $1.49 million from health workforce initiatives, $2.16 million from rural healthcare, $5 million from medical facilities, $20.5 million from mental health hospital construction, and $3.3 million from water resources projects. All transfers align with recommendations from the Joint Committee on Pandemic Relief Funding. The bill takes effect July 1, 2025, and was enacted without the governor's signature on May 29, 2025.
SB 176 requires health insurance plans to cover certain prescription drugs that were previously not included in standard coverage. It directly affects health insurance providers and policyholders by mandating this specific coverage for eligible medications. The key provision is a new requirement for all health benefit plans to include these designated prescriptions without prior authorization or excessive cost-sharing. The law became effective on May 29, 2025, after the Governor did not sign it.
HB 2013, "Dylan's Law," requires health insurance companies to cover epilepsy treatments equally to other conditions, prohibits dropping coverage solely due to an epilepsy diagnosis, and mandates coverage for medically necessary neurostimulation devices. It also allows individuals with epilepsy (diagnosed by a licensed doctor) to voluntarily add a unique symbol to their Oklahoma driver's license or ID card by June 1, 2026, to help first responders identify their condition during emergencies. The symbol cannot be used for any other purpose and may be removed at any time. These provisions became law on May 25, 2025, without a gubernatorial signature. The bill directly affects people with epilepsy and insurers operating under the Affordable Care Act in Oklahoma.
HB 2052 exempts certain domestic health maintenance organizations (HMOs) that exclusively contract with Oklahoma's Medicaid program (via the Oklahoma Health Care Authority) from most state health insurance regulations. These HMOs, which serve only Medicaid recipients and no other patients, are no longer subject to specific provisions of the Health Maintenance Organizations Act, including requirements about benefit coverage and certain administrative rules. The exemption applies solely to services provided to Medicaid recipients under Oklahoma Statutes Title 56, Section 4002.2. The law became effective November 1, 2025, after passing without the Governor's signature.
SB 927 amends Oklahoma's Medicaid Drug Utilization Review Board procedures by prohibiting the pharmaceutical industry representative from voting on drug-related matters. It updates the appointment process to stagger initial terms for one physician, one pharmacist, and the lay representative to ensure board continuity. The bill affects the Oklahoma Health Care Authority and the board members, with changes taking effect November 1, 2025. The board's composition (10 members: 4 physicians, 4 pharmacists, 1 lay representative, 1 pharmaceutical industry rep) and appointment lists remain unchanged.
SB 95 updates key definitions in Oklahoma's workers' compensation law to clarify eligibility and claims processing. It directly affects injured workers (claimants), employers, insurance carriers, and medical providers by defining terms like "case manager" (requiring specific nursing licenses or certifications) and "carrier" (explicitly including self-insured employers). The bill also clarifies what constitutes a "compensable injury," excluding age-related conditions like arthritis and adding drug testing rules for claims involving intoxication. These changes aim to standardize claims administration and reduce disputes over coverage. The bill became effective after the governor signed it on May 6, 2025.
HB 1601, the "ARCHER Act," extends maternity leave protections for eligible public school teachers in Oklahoma. It amends existing sick leave rules (70 O.S. § 6-104.8) to require school districts to provide extended leave for teachers who have worked at least 1,250 hours in the past year, specifically covering pregnancy-related needs beyond standard sick leave. The bill creates a dedicated exception to current sick leave policies, ensuring teachers can take leave for maternity without losing pay, aligning with federal Family and Medical Leave Act (FMLA) standards. This directly affects full-time classroom teachers in public school districts who meet the employment threshold. The law became effective after Governor approval on May 6, 2025.
HB 2087 modifies Oklahoma's income tax credit for donations to qualified research institutes. It adjusts annual funding caps: for biomedical research institutes, the limit drops from $2 million to $1.5 million per year starting in 2026, while cancer research institute credits are capped at $500,000 annually. The credit percentage for each donation type is recalculated yearly based on prior-year claims, using specific formulas to stay within these new limits. Taxpayers donating to qualifying nonprofit biomedical or cancer research institutes (defined by NIH funding requirements) can claim the credit, with individual limits of $1,000-$25,000 depending on filing status or business type.
